Blood filter shows promise for severe psoriasis in early trial

NCT ID NCT06640114

Completed Disease control Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed pilot study tested whether filtering inflammatory molecules from the blood using a device called Efferon CT can help people with severe psoriasis. Sixty adults with moderate to severe plaque psoriasis received the treatment, which involves circulating blood through a special filter for 2 to 6 hours. Researchers measured changes in skin symptoms and quality of life to see if this approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efferon CT device (blood filter that removes inflammatory molecules)
What this could lead to: If successful, this could offer a new treatment option for severe psoriasis by filtering out inflammatory substances from the blood.
What could go wrong: This is a small pilot study with only 60 participants and no control group, so results may not be conclusive. The procedure involves blood filtering and carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

North-Western State Medical University named after I.I. Mechnikov (NWSMU)

Saint Petersburg, Russia
North-Western district scientific and clinical center named after L. G. Sokolov Federal Medical and Biological Agency

Saint Petersburg, 194291, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.